Project Grant R43HL184633
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $345K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Springfield, OH 45503, USA
Similar Awards
- The National Institutes of Health National Heart Lung and Blood Institute awarded Nimble Surgical Incorporated $314,362 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop FLEXLOCK, a manually operable anchoring guide catheter designed to simplify transradial complex percutaneous coronary interventions. FLEXLOCK delivers simultaneous active and passive support through an anchoring tip to provide stable coronary access during complex PCI...
- The National Heart, Lung, and Blood Institute awarded Minnesota Healthsolutions Corporation $329,537 on August 15, 2026, to develop a novel balloon angioplasty inflation device under the Cardiovascular Diseases Research program (CFDA 93.837). The recipient will design and evaluate a prototype inflation device intended to improve safety and efficacy during percutaneous balloon angioplasty by accounting for molecular composition and elasticity differences in arterial tissue. Current market devices...
- The National Heart, Lung, and Blood Institute awarded Vantis Vascular Inc. (doing business as Crossliner Inc.) $496,437 on September 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to advance commercial readiness of a novel guide extension catheter for complex percutaneous coronary interventions. Vantis Vascular is developing a multi-functional guide extension catheter that combines deeper catheter intubation with a microcatheter leading tip and pre-dilatation...
- The National Heart, Lung, and Blood Institute awarded Bridgesource Medical, Corp. $320,727 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a right heart catheter device that uses pressure-volume loop analysis to identify which patients with tricuspid regurgitation will benefit from percutaneous valve repair procedures. The device addresses a critical clinical gap in patient selection for tricuspid valve interventions. Approximately 1.5 million...
- The National Heart, Lung, and Blood Institute awarded Coridea, LLC $305,365 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop cooled radiofrequency bronchoscopic lung volume reduction technology for severe emphysema patients. The project addresses a clinical gap in lung volume reduction therapy. Current surgical options reach only a fraction of severe emphysema patients: wedge excision LVR surgery is invasive and limits candidate eligibility, while...
- The National Heart, Lung, and Blood Institute awarded MDC Studio, Inc. $309,813 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop an automated vascular access device that enables less-experienced providers to safely and reliably perform central venous and arterial cannulation. The R61 phase focuses on automating the core steps of successful cannulation. MDC Studio will design, construct, and test sensors and automation to detect blood vessel...
- The National Heart, Lung, and Blood Institute awarded Baylor College of Medicine $248,993 on June 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop metasurface optical guidewires for treating coronary artery calcification during percutaneous coronary intervention. The award funds design and manufacture of sub-millimeter meta-surface optics for optical guidewires, development of optimized PCI workflows for laser-induced intravascular lithotripsy, and...
- The National Heart, Lung, and Blood Institute awarded Aust Development, LLC a Phase I Small Business Innovation Research project grant of $626,604 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837). Aust Development will develop a novel 3D pre-shaped delivery catheter platform to enable precise identification and safe delivery of cardiac conduction system pacing leads. The delivery system will allow physicians to sequentially map the septal myocardium, fix...
- The National Heart, Lung, and Blood Institute awarded $351,388 to Barron Associates, Inc. on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a noninvasive hemodynamic monitoring tool for heart failure patients. The project addresses the clinical gap in home and hospital monitoring of acute decompensated heart failure by creating a low-cost alternative to invasive right heart catheterization and costly implantable devices. The proposed solution...
- The National Heart, Lung, and Blood Institute awarded Biochip Labs Inc. $321,229 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to manufacture and analytically validate the Microfluidic Impedance Red Cell Assay (MIRCA) for commercial viability. This Small Business Technology Transfer Phase I/II Fast-Track award funds scaling up manufacturing of the microfluidic biochip component with appropriate specifications and tight tolerances under regulated...